Dr. Miguel Arce Rentería, a neuropsychologist at Columbia University, comments that treatment that focuses on social issues may hold off the worst of Alzheimer’s Disease for years.
Neuropsychologist Victoria M. Leavitt, PhD is featured in three EveryDay Health podcasts about recognizing and treating patients with mild cognitive impairment.
A new collaborative study by Drs. Martin Picard and Philip L. De Jager examines the potential link between the brain's mitochondria and a person's psychological stress.
Yaakov Stern, PhD, Florence Irving Professor of Neuropsychology in the Department of Neurology at Columbia University Irving Medical Center talks about his research on cognition and aging.
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.
Other researchers are not convinced that these biomarkers vary by race, primarily because so little Alzheimer’s research has been conducted on Black and Latinx people.
It is well established that people who had fewer opportunities to receive education when they were children are at higher risk for Alzheimer’s disease later in life, noted Dr. Jennifer Manly
During March, Women’s History Month, CUMC is sharing the stories of some of the many women who are spearheading innovation through research, patient care, and education.